Aurinia Pharmaceuticals Inc.

AUPH

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001600620

A

strongest fifth of 370 graded peers in healthcare

rank 65 of 370; percentile 17.3; sampling error 2.5 points; lower is stronger


A B C D E

A, the bull




Scoreboard	
Profitability	D percentile 67.1
Solvency	B percentile 26.3
Growth and financing	A/B percentile 17.7
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $751.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Feb 26, 2026 237 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$16.75 2026-10-20; market equity $2.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis ("LN"). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor ("BAFF") and a proliferation-inducing ligand ("APRIL") for the potential treatment of autoimmune diseases.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 67.1						
Gross profitability	33.3%	32.3%		43.5	371	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	23.3%	(6.6%)		95.6	812	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	3.8 pts	2.8 pts		62.2	242	2025-12-31
Solvency, sleeve percentile 26.3						
Twelve-month failure probability	not computable	0.06%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	5.18	(0.30)		18.3	757	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	5.25x	2.96x		34.3	840	2025-12-31
Growth and financing, sleeve percentile 17.7						
Revenue growth, three-year compound	28.3%	10.1%		23.2	414	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	16.9%	2.1%		24.3	705	2025-12-31
Net share issuance, one year	(3.2%)	2.4%		5.5	633	2026-02-25

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
60	RxSight, Inc. (RXST)	16.0	A	fortress balance sheet
61	Ensign Group, Inc. (ENSG)	16.3	A	fortress balance sheet
62	Natures Sunshine Products Inc. (NATR)	16.5	A	fortress balance sheet
63	Definium Therapeutics, Inc. (DFTX)	16.8	A	dilution
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.1	A	
65	Aurinia Pharmaceuticals Inc. (AUPH)	17.3	A	
66	Acadia Pharmaceuticals Inc. (ACAD)	17.6	A/B	
67	UFP Technologies Inc. (UFPT)	17.9	A/B	
68	Conmed Corp. (CNMD)	18.2	A/B	
69	Dexcom Inc. (DXCM)	18.4	A/B	fortress balance sheet
70	Orthofix Medical Inc. (OFIX)	18.7	A/B	

What the price implies

at the 2026-10-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	45.8%	8.0%	74
Distance from 52-week high	(10.1%)	(29.7%)	77
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.28	0.28	50

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.13	0.30	31
Composite equity issuance, five years	4.3%	20.5%	32
Relative strength against the sector, log excess return	0.16	(0.13)	74

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$179.7M
Operating cash flow, four quarters	$175.2M
Months of runway	not finite
Days since last periodic filing	76 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$13.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$283.1M	2025-12-31	2026-02-26	10-K	26-000017
2	cost of revenue	us-gaap:CostOfRevenue	$32.7M	2025-12-31	2026-02-26	10-K	26-000017
3	assets	us-gaap:Assets	$751.6M	2025-12-31	2026-02-26	10-K	26-000017
4	net income	us-gaap:NetIncomeLoss	$287.2M	2025-12-31	2026-02-26	10-K	26-000017
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$135.7M	2025-12-31	2026-02-26	10-K	26-000017
6	assets	us-gaap:Assets	$550.6M	2024-12-31	2026-02-26	10-K	26-000017
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$235.1M	2024-12-31	2026-02-26	10-K	26-000017
8	cost of revenue	us-gaap:CostOfRevenue	$28.2M	2024-12-31	2026-02-26	10-K	26-000017
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$175.5M	2023-12-31	2026-02-26	10-K	26-000017
10	cost of revenue	us-gaap:CostOfRevenue	$14.1M	2023-12-31	2026-02-26	10-K	26-000017
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$134.0M	2022-12-31	2025-02-27	10-K	25-000011
12	cost of revenue	us-gaap:CostOfRevenue	$5.7M	2022-12-31	2025-02-27	10-K	25-000011
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$45.6M	2021-12-31	2024-02-15	10-K	24-000012
14	cost of revenue	us-gaap:CostOfRevenue	$1.1M	2021-12-31	2024-02-15	10-K	24-000012
15	current assets	us-gaap:AssetsCurrent	$492.0M	2025-12-31	2026-02-26	10-K	26-000017
16	current liabilities	us-gaap:LiabilitiesCurrent	$93.7M	2025-12-31	2026-02-26	10-K	26-000017
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$649.4M	2025-12-31	2026-02-26	10-K	26-000017
18	operating income	us-gaap:OperatingIncomeLoss	$104.9M	2025-12-31	2026-02-26	10-K	26-000017
19	book equity	us-gaap:StockholdersEquity	$581.3M	2025-12-31	2026-02-26	10-K	26-000017
20	liabilities	us-gaap:Liabilities	$170.3M	2025-12-31	2026-02-26	10-K	26-000017
21	operating income	us-gaap:OperatingIncomeLoss	-$91.7M	2023-12-31	2026-02-26	10-K	26-000017
22	interest expense	us-gaap:InterestExpense	$2.8M	2023-12-31	2024-02-15	10-K	24-000012
23	assets	us-gaap:Assets	$548.1M	2023-12-31	2025-02-27	10-K	25-000011
24	assets	us-gaap:Assets	$470.9M	2022-12-31	2024-02-15	10-K	24-000012
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	132,970,979	2026-02-25	2026-02-26	10-K	26-000017
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	137,339,016	2025-02-25	2025-02-27	10-K	25-000011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.